SCHEMBL1736320

SCHEMBL1736320

N#Cc1cc([N+](=O)[O-])c(O)c(C(F)(F)F)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 3/20 0.51
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
CTSB P07858 1/20 0.40
GPR35 Q9HC97 3/20 0.40
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
TTR P02766 1/20 0.39
MTOR P42345 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11690247 0.81 VCAM1 (0.51) VCAM1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL2082866 0.80 VCAM1 (0.61) VCAM1GRIN2DGRIN3BGRIN1GRIN2A
Nitroxinil SCHEMBL166956 0.79 TTR (0.60) VCAM1GRIN2DGRIN3BGRIN1GRIN2A
Nitroxinil SCHEMBL31425481 0.79 TTR (0.60) VCAM1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL9899661 0.79 VCAM1 (0.56) VCAM1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL4167481 0.78 VCAM1 (0.59) VCAM1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL3647954 0.78 VCAM1 (0.47) VCAM1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL11711960 0.78 VCAM1 (0.54) VCAM1MEN1ALDH1A1MAPTKMT2A
SCHEMBL24909372 0.77 VCAM1 (0.51) VCAM1MEN1ALDH1A1MAPTKMT2A
SCHEMBL10886742 0.77 GPR35 (0.59) GPR35MEN1ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1954287-B2 CETP INHIBITORS MERCK SHARP & DOHME (US) 2016-02-24 EP disclosed
US-8334290-B2 CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2012-12-18 US disclosed
EP-1954287-B1 CETP INHIBITORS MERCK SHARP & DOHME (US) 2011-11-16 EP disclosed
US-20110262658-A1 PROCESS AND DEVICE FOR TREATING THE COATING OF THERMOPLASTIC RESIN CONTAINERS ZOPPAS MATTEO 2011-10-27 US disclosed
US-20090264405-A1 Cetp Inhibitors MERCK SHARP & DOHME LLC 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264405-A1 Cetp Inhibitors CETP, APOB, PCSK9 VCAM1 747/4885GRIN2D 4875/4885GRIN3B 4758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.